Amicus Therapeutics Inc. raised $201 million from an underwritten offering of common shares.
The Cranbury, N.J.-based company issued 18,720,930 shares at $10.75 apiece, which included the purchase of additional shares by underwriters.
Amicus Therapeutics plans to use the proceeds for the development of its expanded gene therapy pipeline and manufacturing capabilities for Pompe biologic AT-GAA and gene therapy product candidates.
The proceeds will also be used to complete the design and construction of the Amicus Process Science and Gene Therapy Manufacturing facility as well for general corporate and product development purposes.
J.P. Morgan Securities LLC, Goldman Sachs & Co. LLC and SVB Leerink LLC acted as joint book-running managers for the offering.